News
A new study published in Mucosal Immunology shows that α-galactosylceramide (α-GalCer) serves as a potent adjuvant by activating natural killer T (NKT) cells, which promote effective cross ...
The patent claims include coverage of GRI-0803, the Company’s novel activator of human type 2 diverse NKT (dNKT) cells in development for the treatment of autoimmune disorders, with an initial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback